ZA9810130B - Tumor-specific antigens methods for their production and their use for imunization and diagnosis - Google Patents
Tumor-specific antigens methods for their production and their use for imunization and diagnosisInfo
- Publication number
- ZA9810130B ZA9810130B ZA9810130A ZA9810130A ZA9810130B ZA 9810130 B ZA9810130 B ZA 9810130B ZA 9810130 A ZA9810130 A ZA 9810130A ZA 9810130 A ZA9810130 A ZA 9810130A ZA 9810130 B ZA9810130 B ZA 9810130B
- Authority
- ZA
- South Africa
- Prior art keywords
- imunization
- tumor
- diagnosis
- production
- specific antigens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97119404 | 1997-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA9810130B true ZA9810130B (en) | 1999-05-06 |
Family
ID=8227582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA9810130A ZA9810130B (en) | 1997-11-06 | 1998-11-05 | Tumor-specific antigens methods for their production and their use for imunization and diagnosis |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1029050A1 (en) |
JP (1) | JP2001522603A (en) |
KR (1) | KR20010024585A (en) |
CN (1) | CN1278865A (en) |
AR (1) | AR017562A1 (en) |
AU (1) | AU743066B2 (en) |
BR (1) | BR9813981A (en) |
CA (1) | CA2309557A1 (en) |
TR (1) | TR200001253T2 (en) |
WO (1) | WO1999024566A1 (en) |
ZA (1) | ZA9810130B (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10347710B4 (en) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Recombinant vaccines and their use |
DE102005046490A1 (en) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency |
CA2836494C (en) | 2011-05-24 | 2023-01-03 | Biontech Ag | Individualized vaccines for cancer |
WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
US10155031B2 (en) | 2012-11-28 | 2018-12-18 | Biontech Rna Pharmaceuticals Gmbh | Individualized vaccines for cancer |
WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
CN113791220A (en) | 2014-09-10 | 2021-12-14 | 豪夫迈·罗氏有限公司 | Immunogenic mutant peptide screening platform |
WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
AU2016275030B2 (en) | 2015-06-10 | 2021-12-09 | Nantkwest, Inc. | Modified NK-92 cells for treating cancer |
WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
EP3399861A4 (en) | 2016-01-07 | 2019-08-07 | Mayo Foundation for Medical Education and Research | Methods of treating cancer with interferon |
IL260988B2 (en) * | 2016-03-03 | 2023-03-01 | Roussy Inst Gustave | Ptps-based vaccines against cancer |
KR20190049887A (en) | 2016-09-29 | 2019-05-09 | 난트케이웨스트, 인크. | HLA class I-deficient NK-92 cells with reduced immunogenicity |
KR102528384B1 (en) | 2017-01-06 | 2023-05-02 | 이뮤너티바이오, 인크. | Genetically Modified NK-92 Cells with Reduced CD96/TIGIT Expression |
CN111465989A (en) * | 2017-10-10 | 2020-07-28 | 磨石肿瘤生物技术公司 | Identification of neoantigens using hot spots |
EP3703735A1 (en) | 2017-11-01 | 2020-09-09 | Nantkwest, Inc. | Nk-92 cells to stimulate anti-cancer vaccine |
US20210040451A1 (en) | 2018-01-31 | 2021-02-11 | Nantkwest, Inc. | Use of 5% human albumin in wash and harvest media |
WO2019177986A1 (en) | 2018-03-12 | 2019-09-19 | Nantkwest, Inc. | Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity) |
WO2019226649A1 (en) | 2018-05-22 | 2019-11-28 | Nantkwest, Inc. | Optimization of nk-92 cell growth using poloxamer |
WO2019226521A1 (en) | 2018-05-22 | 2019-11-28 | Nantkwest, Inc. | Basal media for growing nk-92 cells |
AU2019272608B2 (en) | 2018-05-22 | 2023-04-20 | Immunitybio, Inc. | Fc-epsilon CAR |
EP3820994A1 (en) | 2018-07-10 | 2021-05-19 | Nantkwest, Inc. | Generating cik nkt cells from cord blood |
WO2020014245A1 (en) | 2018-07-10 | 2020-01-16 | Nantkwest, Inc. | Cryopreservation |
WO2020028654A1 (en) | 2018-08-01 | 2020-02-06 | Nantkwest, Inc. | Combined invasion and cytotoxicity assay using chemokine secreting target cells |
CA3107101A1 (en) | 2018-08-01 | 2020-02-06 | Nantkwest, Inc. | Chemokine responsive activated natural killer cells with secondary homing activation for verified targets |
IL296050A (en) | 2018-08-01 | 2022-10-01 | Immunitybio Inc | A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies |
US11547727B2 (en) | 2018-11-06 | 2023-01-10 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells |
AU2019388876A1 (en) | 2018-11-26 | 2021-05-20 | Immunitybio, Inc. | IL-2 Dependent NK-92 cells with stable Fc receptor expression |
CN110491450B (en) * | 2019-08-23 | 2023-05-16 | 深圳市新合生物医疗科技有限公司 | Tumor neogenesis antigen prediction platform and application thereof |
US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
WO2023081163A1 (en) | 2021-11-02 | 2023-05-11 | Immunitybio, Inc. | Natural killer cells for chordoma therapy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
-
1998
- 1998-11-02 EP EP98965649A patent/EP1029050A1/en not_active Withdrawn
- 1998-11-02 KR KR1020007004947A patent/KR20010024585A/en not_active Application Discontinuation
- 1998-11-02 TR TR2000/01253T patent/TR200001253T2/en unknown
- 1998-11-02 BR BR9813981-9A patent/BR9813981A/en not_active IP Right Cessation
- 1998-11-02 WO PCT/EP1998/006921 patent/WO1999024566A1/en not_active Application Discontinuation
- 1998-11-02 JP JP2000520561A patent/JP2001522603A/en active Pending
- 1998-11-02 AU AU21518/99A patent/AU743066B2/en not_active Ceased
- 1998-11-02 CN CN98810896A patent/CN1278865A/en active Pending
- 1998-11-02 CA CA002309557A patent/CA2309557A1/en not_active Abandoned
- 1998-11-05 AR ARP980105575A patent/AR017562A1/en unknown
- 1998-11-05 ZA ZA9810130A patent/ZA9810130B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20010024585A (en) | 2001-03-26 |
CA2309557A1 (en) | 1999-05-20 |
WO1999024566A1 (en) | 1999-05-20 |
BR9813981A (en) | 2000-09-26 |
CN1278865A (en) | 2001-01-03 |
TR200001253T2 (en) | 2000-11-21 |
JP2001522603A (en) | 2001-11-20 |
AU743066B2 (en) | 2002-01-17 |
AR017562A1 (en) | 2001-09-12 |
EP1029050A1 (en) | 2000-08-23 |
AU2151899A (en) | 1999-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA9810130B (en) | Tumor-specific antigens methods for their production and their use for imunization and diagnosis | |
IL126811A0 (en) | Human b-cell antigens and related reagents | |
PL330111A1 (en) | Concentyratyed antibody preparation | |
ZA959336B (en) | Antibodies | |
AU1704099A (en) | Monoclonal human natural antibodies | |
GB9603256D0 (en) | Antibodies | |
HUP0104774A3 (en) | Streptococcus antigens | |
EP1039834A4 (en) | Optoacoustic contrast agents and methods for their use | |
AU6266899A (en) | Methods for producing human tumor antigen specific antibodies | |
IL136308A0 (en) | Antipicornaviral compounds and methods for their use and preparation | |
NZ279605A (en) | T-cell antigen receptor v region production and use | |
AU7180198A (en) | Human breast tumor-specific proteins | |
HUP0000318A3 (en) | Tumor vaccine and process for the preparation thereof | |
GB9806666D0 (en) | Antigen preparation and use | |
AU7676300A (en) | Human anti-adipocyte monoclonal antibodies and their use | |
HU9802132D0 (en) | Biphenyl-sulfonyl-cyanamides, process for producing them and their medical use | |
GB9714971D0 (en) | Assays,therapeutic methods and means | |
EP0888126A4 (en) | Anti-idiotypic antibody vaccines | |
CZ20011896A3 (en) | Immunogenic preparation and antibody | |
ZA941645B (en) | Antibodies specifically reactive against human prostate specific antigen. | |
AU1135595A (en) | Saccharomyces-specific antigens and antibodies, their preparation and use | |
AU3753499A (en) | Colon cancer-associated antigens and their diagnostic and therapeutic uses | |
GB9726147D0 (en) | Antigens | |
AU2003204605A1 (en) | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof | |
ZA973643B (en) | Metastasis-associated antigen and antibodies thereto. |